| This week's sponsor is CMIC Group. | | | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Urovant slips as generic holds its own against overactive bladder drug in phase 3 Biogen-Nightstar deal sheds light on gene therapy feeding frenzy ACC: After acing early trial, PhaseBio pushes forward with Brilinta-reversing drug Unlocking a secret of the anti-cancer gene p53 Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients Featured Story | | | Tuesday, March 19, 2019 Urovant Sciences’ vibegron has hit the co-primary endpoints in a phase 3 overactive bladder trial. But with the drug failing to clearly outperform a generic used as an active control, the results leave room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq. |
|
|
Top Stories Tuesday, March 19, 2019 The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics. Biogen ultimately landed its target with an $877 million (€772 million) all-cash offer, but only after seeing off interest from three other companies. Tuesday, March 19, 2019 PhaseBio reported phase 1 data for its Brilinta (ticagrelor) reversal agent on Sunday that showed the drug quickly reversed the antiplatelet effects of Brilinta without causing serious side effects. The company plans to kick off a phase 2a study in the first half of this year. Monday, March 18, 2019 The gene p53 has long been a target of intense research in the oncology community because, in its unaltered form, it suppresses cancer. Now a team at the University of Wisconsin-Madison has discovered an enzyme that acts as a key regulator of the p53 protein, a finding they believe could inspire new ideas for targeting p53 with drugs. Tuesday, March 19, 2019 AbbVie and Roche are looking to move key oncology drug Venclexta deeper into the blood cancer arena, but their ambitions just took a hit. After flagging deaths in a phase 3 multiple myeloma trial, the FDA put all of Venclexta's studies in that disease on partial hold. | This week's sponsor is Accenture. | | | [Webinar] Embracing Emerging Technology in Drug Development
Wednesday, March 27 | 10am ET / 7am PT
During this webinar, attendees will learn how organizations can rapidly adopt digital solutions while maintaining a focus on the patient, harmonize a rapidly transforming workforce with new technological capabilities, and align new technologies with an organization's R&D strategy and goals for profitable growth. Register Now! |
Resources Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! Calling Europe – Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 